We are live on
!
Find out more
CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
1-Year Est. Return
37.91%
This Fund
S&P 500
This Quarter
Est. Return
-13.64%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$53.1M
AUM Growth
-$53.4M
(-50%)
Cap. Flow
-$44.5M
Cap. Flow
% of AUM
-83.85%
Top 10 Holdings %
Top 10 Hldgs %
89.08%
Holding
21
New
4
Increased
2
Reduced
7
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$6.92M |
| 2 |
Merck
MRK
|
+$5.06M |
| 3 |
Illumina
ILMN
|
+$3.51M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$3.08M |
| 5 |
AGN
Allergan plc
AGN
|
+$2.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DaVita
DVA
|
+$12.6M |
| 2 |
Stryker
SYK
|
+$7.53M |
| 3 |
NUVA
NuVasive, Inc.
NUVA
|
+$6.19M |
| 4 |
CVS Health
CVS
|
+$5.98M |
| 5 |
Edwards Lifesciences
EW
|
+$5.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Illumina
ILMN
$29.8B
| $6.25M | 11.76% |
21,411
+11,335
| +112% | +$3.51M |
|
|
2
Gilead Sciences
GILD
$162B
| $6.19M | 11.66% |
+99,000
| New | +$6.92M |
|
3
Intuitive Surgical
ISRG
$119B
| $5.56M | 10.46% |
34,818
-30,825
| -47% | -$5.22M |
|
4
Vertex Pharmaceuticals
VRTX
$120B
| $5.45M | 10.26% |
32,883
-30,024
| -48% | -$5.2M |
|
|
5
Merck
MRK
$322B
| $5.23M | 9.85% |
+71,747
| New | +$5.06M |
|
6
Thermo Fisher Scientific
TMO
$213B
| $4.25M | 8% |
19,000
-1,206
| -6% | -$283K |
|
|
7
CVS Health
CVS
$136B
| $3.93M | 7.39% |
59,956
-80,053
| -57% | -$5.98M |
|
8
Zoetis
ZTS
$31.3B
| $3.89M | 7.32% |
45,439
-10,021
| -18% | -$903K |
|
|
9
Stryker
SYK
$122B
| $3.86M | 7.27% |
24,626
-45,026
| -65% | -$7.53M |
|
|
WCG
10
DELISTED
Wellcare Health Plans, Inc.
WCG
| $2.71M | 5.11% |
+11,500
| New | +$3.08M |
|
11
Heron Therapeutics
HRTX
$86.9M
| $2.41M | 4.54% |
93,000
+50,178
| +117% | +$1.38M |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $2M | 3.77% |
+15,000
| New | +$2.46M |
|
13
CareDx
CDNA
$1.94B
| $1.38M | 2.6% |
54,976
-10,024
| -15% | -$258K |
|
|
14
DaVita
DVA
$15B
| – | – |
-176,403
| Closed | -$12.6M |
|
15
Elanco Animal Health
ELAN
$12.4B
| – | – |
-51,000
| Closed | -$1.78M |
|
|
16
Edwards Lifesciences
EW
$48.3B
| – | – |
-97,632
| Closed | -$5.67M |
|
|
FOLD
17
CALL
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-80,000
| Closed | -$967K |
|
|
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-458,630
| Closed | -$5.54M |
|
19
Henry Schein
HSIC
$9.63B
| – | – |
-69,568
| Closed | -$4.64M |
|
|
PDCO
20
DELISTED
Patterson Companies, Inc.
PDCO
| – | – |
-170,000
| Closed | -$4.16M |
|
|
NUVA
21
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-87,205
| Closed | -$6.19M |
|
Similar funds
AAM
IR
YEPV
LC
MA
IFC
PVMCV
ARTA
Copernicus Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Copernicus Capital Management held 21 positions worth $53.1M, down 50% from $107M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Copernicus Capital Management withdrew a net $44.5M in Q4 2018, closing 8 positions and reducing 7 holdings. Its most notable exit was DaVita, an estimated $12.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.
Against the trend, Copernicus Capital Management opened a new position in Gilead Sciences worth $6.19M.
- Copernicus Capital Management's largest Q4 2018 buy was Gilead Sciences: 99,000 shares worth $6.19M.
- Copernicus Capital Management added most to Illumina in Q4 2018, an estimated $3.51M increase.
- Copernicus Capital Management's biggest Q4 2018 reduction was Stryker, cutting an estimated $7.53M.
- Copernicus Capital Management fully exited DaVita in Q4 2018, selling an estimated $12.6M.
- Copernicus Capital Management's ten largest holdings make up 89% of its $53.1M portfolio in Q4 2018.
- Copernicus Capital Management opened 4 new positions and closed 8 in Q4 2018.
- Copernicus Capital Management's portfolio value fell 50% quarter-over-quarter to $53.1M.
Based on Copernicus Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.